Theratechnologies Inc. (TH.TO) TSX
Currency In CAD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CAD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
103
First IPO Date
August 06, 1996
| Name | Title | Pay | Year Born |
| Paul Lévesque | President, Chief Executive Officer & Director | 1.8M | 1964 |
| Jocelyn Lafond | General Counsel & Corporate Secretary | 547,266 | 1968 |
| Christian Marsolais | Senior Vice President & Chief Medical Officer | 690,437 | 1963 |
| Philippe Dubuc | Senior Vice President & Chief Financial Officer | 708,301 | 1967 |
| John Leasure | Global Commercial Officer | 811,531 | 1965 |
| Andre Dupras | Vice President of Human Resources | 0 | 1964 |
| Joanne Choi | Senior Director of Investor Relations | 0 | N/A |
| Julie Schneiderman | Senior Director, Communications & Corporate Affairs | 0 | N/A |
Theratechnologies Inc. is a biopharmaceutical firm dedicated to developing and bringing to market a range of treatments aimed at fulfilling critical medical needs across the US, Canada, and Europe. Its current product portfolio includes EGRIFTA and EGRIFTA SV, designed to lessen excessive abdominal fat in HIV patients suffering from lipodystrophy. Additionally, it provides Trogarzo, an ibalizumab injection, used to treat individuals with multidrug-resistant HIV-1. The company's future product pipeline features the F8 Formulation, also targeting lipodystrophy in HIV-positive individuals. Furthermore, TH1902 is undergoing Phase 1/Part A clinical trials for triple-negative breast cancer, and TH1904 is being developed for ovarian cancer. Established in 1993, the company maintains its headquarters in Montreal, Canada.